Literature DB >> 1995265

Natural killer cell activity in patients with liver cirrhosis relative to severity of liver damage.

W L Chuang1, H W Liu, W Y Chang, S C Chen, M Y Hsieh, L Y Wang.   

Abstract

To evaluate the role of severe liver damage on natural killer cell activity, 29 patients with liver cirrhosis were examined. The natural killer cell activity was measured with a 4-hr chromium release assay, and the K562 cell line was employed as target cells. The natural killer cell activity was significantly decreased in cirrhotic patients compared with normal controls and patients with chronic active hepatitis. Cirrhotic patients with Pugh's C grade of severity of liver disease had lower natural killer cell activity. The depression of natural killer cell activity in cirrhotic patients was inversely correlated with prothrombin time ratios, and the natural killer cell activity in cirrhotic patients with hepatic encephalopathy was lower than in patients without hepatic encephalopathy. Thus, the diminished natural killer cell activity in cirrhotic patients might be related to the severity of liver damage.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1995265     DOI: 10.1007/bf01318200

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  Laboratory control of coumarin therapy: the clinician's dilemma.

Authors:  M J SEIDE
Journal:  Ann Intern Med       Date:  1962-10       Impact factor: 25.391

2.  Natural killer activity in patients with chronic hepatitis treated with OK432, interferon, adenine arabinoside and glycyrrhizin.

Authors:  T Wada; T Arima; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1987-06

3.  Natural killer activity: definition of a function rather than a cell type.

Authors:  J R Ortaldo; C W Reynolds
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

4.  Abnormal natural killer cytotoxicity in primary biliary cirrhosis: evidence for a functional deficiency of cytolytic effector cells.

Authors:  S P James; E A Jones
Journal:  Gastroenterology       Date:  1985-07       Impact factor: 22.682

5.  Deficient natural killer cell activity in alcoholic cirrhosis.

Authors:  B Charpentier; D Franco; L Paci; M Charra; B Martin; D Vuitton; D Fries
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

6.  Acute and chronic hepatitis revisited. Review by an international group.

Authors: 
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

7.  Defective function of lymphokine-activated killer cells and natural killer cells in patients with hepatocellular carcinoma.

Authors:  T Saibara; S Onishi; H Sakaeda; Y Yamamoto
Journal:  Hepatology       Date:  1989-03       Impact factor: 17.425

8.  Natural killer cell activity in post-necrotic cirrhotic patients as related to hepatitis-B virus infection and plasma zinc levels.

Authors:  B Yoffe; S Pollack; E Ben-Porath; O Zinder; D Barzilai; H Gershon
Journal:  Immunol Lett       Date:  1986-11-17       Impact factor: 3.685

9.  Depressed natural killer cell activity in patients with hepatocellular carcinoma. In vitro effects of interferon and levamisole.

Authors:  K Son; M Kew; A R Rabson
Journal:  Cancer       Date:  1982-12-15       Impact factor: 6.860

10.  Impaired concanavalin A-inducible suppressor T-cell activity in active alcoholic liver disease.

Authors:  H Kawanishi; H Tavassolie; R P MacDermott; J N Sheagren
Journal:  Gastroenterology       Date:  1981-03       Impact factor: 22.682

View more
  11 in total

1.  Immunoelectron microscopic observations on Leu-7 positive cells in virus-related chronic liver diseases.

Authors:  H Himeno; H Enzan; T Saibara; S Onishi; Y Yamamoto
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

2.  Natural killing activities in chronic liver diseases and hepatocellular carcinoma.

Authors:  K Ono; Y Yamanaga; K Yamamoto; S I Koga; J Nishimura; H Nawata
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

3.  Immunosuppressive effect of chenodeoxycholic acid on natural killer cell activity in patients with biliary atresia and hepatitis C virus-related liver cirrhosis.

Authors:  Masaru Hirata; Yasushi Harihara; Yoshiaki Kita; Shoichi Saito; Motoko Nishimuraj; Hiroyuki Yoshino; Keiji Sano; Mitsuhiro Ito; Koji Kusaka; Hideo Kawarasaki; Kohei Hashizume; Masatoshi Makuuchi
Journal:  Dig Dis Sci       Date:  2002-05       Impact factor: 3.199

Review 4.  Liver cirrhosis and immune dysfunction.

Authors:  Elda Hasa; Phillipp Hartmann; Bernd Schnabl
Journal:  Int Immunol       Date:  2022-09-06       Impact factor: 5.071

Review 5.  The antifibrotic role of natural killer cells in liver fibrosis.

Authors:  Yuan Wei; Wang Bingyu; Yang Lei; Yuan Xingxing
Journal:  Exp Biol Med (Maywood)       Date:  2022-04-27

Review 6.  Impairment of innate immune responses in cirrhotic patients and treatment by branched-chain amino acids.

Authors:  Ikuo Nakamura
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 7.  Risk factors and outcome of bacterial infections in cirrhosis.

Authors:  Tony Bruns; Henning W Zimmermann; Andreas Stallmach
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

8.  Cellular immune function and liver damage in post-hepatitic cirrhosis.

Authors:  Z J Feng; R M Niu; X L Ren; X X Yao
Journal:  World J Gastroenterol       Date:  1997-03-15       Impact factor: 5.742

9.  Gender different response to immunonutrition in liver cirrhosis with sepsis in rats.

Authors:  Tsann-Long Hwang; Chi-Yi Chen
Journal:  Nutrients       Date:  2012-03-22       Impact factor: 5.717

10.  Thymostimulin in advanced hepatocellular carcinoma: a phase II trial.

Authors:  Matthias M Dollinger; Christa M Behrens; Joachim Lesske; Susanne Behl; Curd Behrmann; Wolfgang E Fleig
Journal:  BMC Cancer       Date:  2008-03-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.